You are viewing the site in preview mode
Skip to main content
|
Double disc diffusion
|
|---|
|
GBS phenotypesa
|
Erythromycin (n)
|
Clindamycin (n)
|
Total (n = 46)
|
Percent (%)
|
|---|
|
R
|
I
|
S
|
R
|
I
|
S
|
|---|
|
Constitutive macrolide, lincosamide–streptogramin B (cMLSB)
|
10
|
2
|
–
|
9
|
3
|
–
|
12
|
26.1
|
|
inducible macrolide, lincosamide–streptogramin B (iMLSB)
|
6
|
1
|
–
|
–
|
–
|
7
|
7
|
15.2
|
|
M-phenotype
|
10
|
3
|
–
|
–
|
–
|
13
|
13
|
28.3
|
|
L-phenotype
|
–
|
–
|
14
|
12
|
2
|
–
|
14
|
30.4
|
|
D-shape positive
|
6
|
1
|
0
|
–
|
–
|
7
|
7
|
15.2
|
|
D-shape negative
|
–
|
–
|
–
|
–
|
–
|
–
|
39
|
84.8
|
- aCLSI disk diffusion breakpoints [18]. Erythromycin: ≥ 21 mm, susceptible (S); 16 to 20 mm, intermediate (I); ≤ 15 mm, resistant (R). Clindamycin: ≥ 19 mm, susceptible (S); 16 to 18 mm, intermediate (I); ≤ 15 mm, resistant (R)
